Broadway has rarely looked healthier on paper. According to the Broadway League, the trade association that compiles official industry data, the 2024-2025 season grossed roughly $1.89 billion and drew about 14.7 million attendances — the highest-grossing season in recorded history, and the second best attended after 2018-2019. Seats filled at 91.2 percent of capacity.
But beneath the record grosses lies a narrower creative pipeline. The same season featured 43 newly opened productions, including 21 musicals — of which 16 were original and 5 were revivals, per the League's figures. Industry observers argue that even the "original" label obscures how heavily new musicals now rely on pre-existing material: songbooks, films, television series and other branded intellectual property.
The economics of a $20 million gamble
The central pressure is cost. Multiple industry analyses put the price of mounting a new Broadway musical at roughly $20 million, with the full range commonly cited between $15 million and $40 million depending on cast size and effects, as outlined in a BroadwayWorld survey of rising production costs. Recent shows have pushed higher still.
Those costs would matter less if shows reliably earned them back. They do not. By BroadwayWorld's accounting, only a handful of new musicals — among them Six, MJ: The Musical and & Juliet — have recouped their capitalization in the post-pandemic period, a rate analysts describe as roughly one in five among recent titles. Even acclaimed revivals have struggled: a Gypsy revival starring Audra McDonald, capitalized at a reported $19.5 million, closed without recouping despite strong reviews. (Recoupment outcomes for individual titles shift over time and should be treated as point-in-time.)
Why familiar IP wins
When a single production can lose $20 million or more, producers gravitate toward titles that arrive with a built-in audience. Two of the most-cited post-pandemic recoupers are jukebox musicals: MJ, built on Michael Jackson's catalog, and & Juliet, built on songs by the hitmaker Max Martin. The slate of new musicals leans similarly on screen properties, with movie-to-stage adaptations recurring among the arrivals.
The logic is defensive rather than purely creative. With average paid admissions topping $130 in some recent weeks, per Broadway grosses data, audiences paying premium prices tend to gravitate toward what feels familiar. A recognizable title comes with name recognition that lowers the cost of persuading a tourist or occasional theatergoer to buy a ticket.
Post-pandemic math
The pandemic sharpened these incentives. Production costs rose with inflation and labor expenses, while the audience that returned skewed toward higher-spending tourists buying fewer, safer tickets. The result is a market where record grosses are driven substantially by higher prices rather than more bodies in seats — attendance in 2024-2025 still trailed the 2018-2019 peak even as grosses surpassed it, the League's numbers show. That dynamic rewards the blockbuster and punishes the experiment.
What it means for the art form
The concern among critics and some practitioners is not that adaptations are inherently inferior — many are accomplished — but that the economics increasingly foreclose the original, idiosyncratic musical that defined the form's history. If the surest path to recoupment runs through known brands, the incentive to develop new stories from scratch weakens.
Defenders note that Broadway has always borrowed from other media, and that a record-grossing industry retains the resources to take occasional swings. The open question is whether those swings become rarer as the price of failure climbs. For now, the data describe an industry that is commercially robust and creatively cautious at the same time — flush with revenue, yet leaning harder than ever on the familiar.
